Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer
نویسندگان
چکیده
BACKGROUND The Stockholm III Trial randomized patients with primary operable rectal cancers to either short-course radiotherapy (RT) with immediate surgery (SRT), short-course RT with surgery delayed 4-8 weeks (SRT-delay) or long-course RT with surgery delayed 4-8 weeks. This preplanned interim analysis examined the pathological outcome of delaying surgery. METHODS Patients randomized to the SRT and SRT-delay arms in the Stockholm III Trial between October 1998 and November 2010 were included, and data were collected in a prospective register. Additional data regarding tumour regression grade, according to Dworak, and circumferential margin were obtained by reassessment of histopathological slides. RESULTS A total of 462 of 545 randomized patients had specimens available for reassessment. Patients randomized to SRT-delay had earlier ypT categories, and a higher rate of pathological complete responses (11·8 versus 1·7 per cent; P = 0·001) and Dworak grade 4 tumour regression (10·1 versus 1·7 per cent; P < 0·001) than patients randomized to SRT without delay. Positive circumferential resection margins were uncommon (6·3 per cent) and rates did not differ between the two treatment arms. CONCLUSION Short-course RT induces tumour downstaging if surgery is performed after an interval of 4-8 weeks.
منابع مشابه
In the literature: April 2017
SHORT-COURSE RADIOTHERAPY FOLLOWED BY DELAYED SURGERY BECOMES A VALIDATED ALTERNATIVE TO TREAT INTERMEDIATE-RISK LOCALISED RECTAL CANCER The full publication in Lancet Oncology of the Stockholm III trial helps us to understand that short-course radiotherapy in patients with localised rectal cancer could also be followed by delayed surgery. During more than 14 years, more than 800 patients with ...
متن کاملEfficacy of Sucralfate Ointment in Prevention of Acute Proctitis in Cancer Patients: a Randomized Controlled Clinical Trial
Background: Acute radiation proctitis (ARP) is a usual adverse effect in patients undergoing pelvic radiotherapy. The symptoms include diarrhea, rectal blood or mucus discharge, fecal urgency and tenesmus with pain. Sucralfate, an aluminum-based salt of sucrose octasulfate, is a cytoprotective agent that forms a coating barrier at injured sites by adhering to mucoproteins. It has been used in t...
متن کاملThe protective effects of melatonin on blood cells of rectal cancer patients following radiation therapy; a randomized controlled trial
Introduction: Rectal cancer is a heterozygous disease in which cancerous cells grow in the rectum and lower parts of the colon. The primary cause of this cancer is not yet known, but factors such as over age 50, smoking, family history, improper diet or having a history of polyps and inflammatory bowel disease are the major risk factors for developing the rectum cancer. The rec...
متن کاملEvaluation of incidence of intestinal complications during radiation therapy in two supine and prone positions in patients with rectal cancer
Introduction: Radiation therapy is one of the main treatments for rectal cancer. In three-dimensional conformal radiotherapy, exposure of healthy tissue around the tumor is unavoidable. The small intestine is the most important organ at risk of rectal cancer radiotherapy. Intestinal complications are a major factor limiting the dose radiotherapy for rectal cancer. The most com...
متن کاملNew drug in neoadjuvant chemoradiation for rectal cancer
Background: In recent years, neoadjuvant chemoradiation and subsequent surgical resection with total mesorectal excision has been shown to increase local control with decreased toxicity. Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer. In this study we evaluated the efficacy a cox-2 inhibitor on pathologic response, sphincter preservation and acute tox...
متن کامل